Adult ADHD: Optimizing Stimulant Therapy

In this episode, we explore the delicate balance of prescribing stimulants for adult ADHD when abuse potential is a concern. How do you distinguish between performance-driven misuse and recreational abuse? Dr. Bukstein shares essential red flags, safety precautions, and strategies to protect both patients and prescribers. Faculty: Oscar G. Bukstein, M.D., M.P.H. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Mastering Adult ADHD: A Comprehensive Clinical Guide Stimulants: Clinical Considerations, Preventing Abuse, and Red Flags

In this episode, we explore groundbreaking research on treating cannabis-induced psychosis with antipsychotic medications. Which formulations cut hospitalization rates by 75%? And why do some commonly prescribed antipsychotics show no effectiveness at all in preventing future psychotic episodes? Faculty: David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 78 Cannabis-Induced Psychosis: Which Antipsychotics Best Prevent Hospitalization?

In this episode, we explore stimulant medications for adult ADHD with Dr. Oscar Bukstein. Why have amphetamines overtaken methylphenidate as the most prescribed option? Discover how to match formulation duration to patient needs, navigate cardiovascular risks, and monitor treatment effectively for optimal outcomes in adult ADHD management. Faculty: Oscar G. Bukstein, M.D., M.P.H. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Mastering Adult ADHD: A Comprehensive Clinical Guide Pharmacologic Treatments for Adult ADHD: Focus on Stimulants

In this episode, we explore the groundbreaking COaST trial examining semaglutide for clozapine-induced weight gain in schizophrenia patients. Could GLP-1 agonists finally offer a real solution to one of psychiatry's most frustrating paradoxes—when the medication that saves lives simultaneously shortens them? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 78 Does Semaglutide Reverse Clozapine-Induced Weight Gain in Schizophrenia? Results from the COaST Trial

In this episode, we explore the treatment algorithm for adult ADHD with Dr. Oscar Bukstein from Harvard Medical School. Should you start with stimulants or non-stimulants when substance use disorder complicates the picture? Discover how comorbidities like depression and anxiety reshape your medication selection strategy for optimal patient outcomes. Faculty: Oscar G. Bukstein, M.D., M.P.H Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Mastering Adult ADHD: A Comprehensive Clinical Guide Treatment Algorithm for Adult ADHD

In this episode, we explore pramipexole—a Parkinson's medication—as a promising add-on treatment for treatment-resistant bipolar depression. Could a dopamine agonist be the unexpected solution when standard mood stabilizers and antipsychotics fail? We examine the PAX-BD trial's findings, safety concerns, and practical clinical applications. Faculty: Kristin Raj, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 78 Treatment-Resistant Bipolar Depression: Is Adjunctive Pramipexole An Option?

In this episode, we explore the controversial role of SERT gene testing in predicting SSRI response with Dr. Chris Aiken. Can genetic testing really tell us which patients will respond to antidepressants, or are we putting too much faith in pharmacogenetic promises that lack solid evidence? Faculty: Chris Aiken, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: The Role of Genetic Testing in Psychiatry SERT Gene and SSRI Response: Is It Clinically Useful?

In this episode, we explore a critical drug interaction: SSRIs combined with anticoagulants increase major bleeding risk by 35-47%. Should age and sex change our prescribing decisions? We break down the evidence from nearly 100,000 patients and discuss safer antidepressant alternatives for high-risk individuals. Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 77 Do SSRIs Increase Major Bleeding Risk with Oral Anticoagulants?

In this episode, we explore the paradox of pharmacogenetic testing with Dr. Chris Aiken: why do these tests consistently fail in clinical trials despite showing promise in understanding drug metabolism? Could industry bias and statistical noise be masking the truth about personalized psychiatric medicine? Faculty: Chris Aiken, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: The Role of Genetic Testing in Psychiatry Pharmacogenetic Panels: Do They Really Work?

In this episode, we explore how Lurasidone at lower doses (20-60 mg/day) effectively treats both depression and anxiety in bipolar I disorder. Why does the lower dose range outperform higher doses for patients with severe anxiety? Discover the surprising dose-dependent effects and metabolic advantages that make this a game-changer. Faculty: Kristin Raj, M.D. Host: Richard Seeber, M.D. Learn more about our membership here. Earn 0.75 CMEs: Quick Take Vol. 77 Is Lurasidone Effective for Bipolar Depression with Comorbid Anxiety?